sodium citrate

Phase 2Small molecule

Eli Lilly

sodium citrate is one of 112 small molecule programs targeting Sepsis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

111

Competitors

Pipeline

Status by Indication[3][1]

Indication

SepsisActive, not recruiting

COVID-19Active, not recruiting

Autosomal Dominant Polycystic Kidney DiseaseActive, not recruiting

Type 1 Diabetes MellitusActive, not recruiting

SepsisPreclinical

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Autosomal Dominant Polycystic Kidney DiseasePhase 2

Active, not recruiting

Type 1 Diabetes MellitusPhase 1

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Spikevax

Moderna

Preclinical

21 2

sodium citrate

Eli Lilly

Phase 2

1 3

Tricor

JJagotec

Preclinical

1 4

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 5

Rayaldee

OOrganon and Co

Preclinical

1 6

Statin

Bristol-Myers Squibb

Preclinical

1 7

Calcium

Olokizumab

1 9

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1 10

Tpa

UUniversity of Florida

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

N/ANot yet recruiting

Sepsis

NCT06994312

Clinical

Trials by Indication[1]

Extracorporeal Membrane Oxygenation1 trial

Study Using Citrate to Replace Heparin in Babies Requiring Extracorporeal Membrane Oxygenation (ECMO)

Completed·VVanderbilt University·Phase 1·NCT00968565·2 enrolled

Cardiac1 trial

Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac Defects

Completed·NNational Center for Research Resources (NCRR)··NCT00004361·150 enrolled

Sepsis1 trial

The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration

Not yet recruiting·TThe First Hospital of Jilin University·N/A·NCT06994312·282 enrolled

Type 1 Diabetes Mellitus1 trial

A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT05067270·40 enrolled

COVID-191 trial

Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction

Active, not recruiting·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT06204432·60 enrolled

3 more indications

Anticoagulation1 trial

Comparison of Biocompatibility of Plasmapheresis Procedures With Citrate and Heparin Anticoagulation

Completed·UUniversity Medical Centre Ljubljana·Phase 4·NCT05191290·15 enrolled

Autosomal Dominant Polycystic Kidney Disease1 trial

Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease

Completed·UUniversity of Southern California·Phase 2·NCT04284657·1 enrolled

Cognitive Functions1 trial

The Impact of Air Travel on Passenger Cognitive Functions

Unknown status·DDinara Zhumanbayeva·Phase 2/3·NCT04802785·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for sodium citrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — sodium citrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for sodium citrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Eli Lilly

sodium citrate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Extracorporeal Membrane Oxygenation1 trial

Cardiac1 trial

Sepsis1 trial

Type 1 Diabetes Mellitus1 trial

COVID-191 trial

Anticoagulation1 trial

Autosomal Dominant Polycystic Kidney Disease1 trial

Cognitive Functions1 trial

References

Drug Info

Quick Facts

Related News